Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Authors
Keywords
-
Journal
Journal of Thoracic Oncology
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-05-04
DOI
10.1016/j.jtho.2023.04.021
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
- (2023) L.E. Hendriks et al. ANNALS OF ONCOLOGY
- Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer with untreated brain metastases.
- (2022) Ernest Nadal et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227
- (2022) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
- (2022) Luis G. Paz-Ares et al. Journal of Thoracic Oncology
- 180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
- (2021) W. Cui et al. Journal of Thoracic Oncology
- EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
- (2021) E. Le Rhun et al. ANNALS OF ONCOLOGY
- Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non–Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407
- (2021) Steven F. Powell et al. Journal of Thoracic Oncology
- 122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
- (2021) M. Reck et al. ANNALS OF ONCOLOGY
- Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
- (2021) Hamid Emamekhoo et al. CANCER
- OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
- (2021) D. Carbone et al. Journal of Thoracic Oncology
- First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
- (2021) Luis G. Paz-Ares et al. Journal of Thoracic Oncology
- Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
- (2021) Hussein A Tawbi et al. LANCET ONCOLOGY
- PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice
- (2020) Iñaki Eguren-Santamaria et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
- (2020) Sarah B Goldberg et al. LANCET ONCOLOGY
- Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review
- (2019) Mark T. J. van Bussel et al. BMC CANCER
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non–small-cell Lung Cancer With Brain Metastasis at Presentation
- (2018) Saiama N. Waqar et al. Clinical Lung Cancer
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine
- (2018) Minjee Kim et al. PHARMACEUTICAL RESEARCH
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid
- (2018) Dick Pluim et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Response Assessment in Neuro-Oncology Clinical Trials
- (2017) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternative metrics for assessing clinical benefit with immunotherapy in oncology
- (2017) E. Chan et al. OncoImmunology
- Estimating Survival in Patients With Lung Cancer and Brain Metastases
- (2017) Paul W. Sperduto et al. JAMA Oncology
- Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
- (2016) Marc C. Chamberlain et al. NEURO-ONCOLOGY
- Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study
- (2015) Denis Moro-Sibilot et al. LUNG CANCER
- The Blood–Brain Barrier
- (2015) Richard Daneman et al. Cold Spring Harbor Perspectives in Biology
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
- (2013) A. Ali et al. Current Oncology
- Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
- (2011) F. Barlesi et al. ANNALS OF ONCOLOGY
- Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer
- (2010) Martin J. Edelman et al. Journal of Thoracic Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started